Fig. 2From: Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer’s disease and frontotemporal dementiaHumoral immune responses induced by tau294–305 epitope to hepatitis B core immunodominant region (T294-HBc) virus-like particle (VLP) vaccine. a Schematic diagram of the time points for treating Tau.P301S mice (5 months old) (n = 7). b The antibody titer induced by T294-HBc VLPs. Sera from immunized mice were serially diluted from 1:100 to 1:819,200 in twofold dilution steps and tested in duplicates by enzyme-linked immunosorbent assay (ELISA) against mis-disordered tau (151–391/2N4R). c The isotypes of vaccine-induced antibodies. The diluted sera were added to mis-disordered tau (151-391/2N4R)-coated plate and followed by adding HRP–conjugated secondary antibodies. d Different binding of serum antibodies to mis-disordered tau (151-391/2N4R) and full-length tau 2N4R. Sera from immunized mice were serially diluted from 1:100 to 1:3906250 in fivefold dilution steps and tested in duplicates by ELISA against mis-disordered tau (151-391/2N4R) and full length tau 2N4R, respectively. EC50, Half-maximal effective concentration. (Statistics were analyzed by student’s t-test, *P<0.05). e The binding activity of the antibody elicited by T294-HBc to different tau fragments. The mixture of 200 μM of different tau fragments with diluted sera was added to the mis-disordered tau-coated plate, and then HRP-conjugated goat anti-mouse immunoglobulin G was added. f The binding activity of the antibodies elicited by T294-HBc to the brain tissues of Tau.P301S mice. Brain tissue was detected via IHC using serum from HBc (1:200)- or T294-HBc (1:200)-treated mice. Scale bar is 200 μmBack to article page